IBB vs. CNCR

Last updated Jun 24, 2026

IBB (iShares Nasdaq Biotechnology ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - IBB tracks the NASDAQ Biotechnology Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. IBB charges 0.47%/yr vs 0.79%/yr for CNCR.

Performance

IBB vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Nasdaq Biotechnology ETF (IBB) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

IBB

• 1D: 0.62%
• 1M: 5.52%
• YTD: 5.61%
• 6M: 3.57%
• 1Y: 42.90%
• 3Y*: 11.80%
• 5Y*: 2.21%
• 10Y*: 8.21%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IBB vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
IBB iShares Nasdaq Biotechnology ETF	4.83%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

IBB vs. CNCR - Sectors Allocation Comparison

Sectors	IBB	CNCR
Healthcare	100.0%	96.6%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

IBB vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBB

IBB Risk / Return Rank: 71
IBB Sharpe Ratio Rank: 68
IBB Sortino Ratio Rank: 68
IBB Omega Ratio Rank: 60
IBB Calmar Ratio Rank: 85
IBB Martin Ratio Rank: 75

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IBB vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	IBB	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	2.12	—	—
Sortino ratio: Return per unit of downside risk	2.96	—	—
Omega ratio: Gain probability vs. loss probability	1.35	—	—
Calmar ratio: Return relative to maximum drawdown	4.47	—	—
Martin ratio: Return relative to average drawdown	13.77	—	—

Drawdowns

IBB vs. CNCR - Drawdown Comparison

The maximum IBB drawdown since its inception was -62.85%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IBB and CNCR.

Drawdown Indicators

	IBB	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-62.85%	0.00%	-62.85%
Max Drawdown (1Y) Largest decline over 1 year	-9.63%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-24.85%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-39.82%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-39.82%	—	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	-21.14%	0.00%	-21.14%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.12%	—	—

Volatility

Volatility by Period

	IBB	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.95%	—	—
Volatility (6M) Calculated over the trailing 6-month period	15.98%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	20.34%	0.00%	+20.34%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	22.03%	0.00%	+22.03%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.17%	0.00%	+23.17%

IBB vs. CNCR - Expense Ratio Comparison

IBB has a 0.47% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

IBB vs. CNCR - Dividend Comparison

IBB's dividend yield for the trailing twelve months is around 0.23%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
IBB iShares Nasdaq Biotechnology ETF	0.23%	0.23%	0.29%	0.26%	0.31%	0.21%	0.21%	0.33%	0.20%	0.30%	0.19%	0.03%

Frequently Asked Questions

Which ETF is better, IBB or CNCR?

On fees, IBB is cheaper at 0.47% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, IBB or CNCR?

IBB is cheaper with a 0.47% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, IBB or CNCR?

IBB has the higher dividend yield at 0.23%, compared with 0.00% for CNCR.

What is the main difference between IBB and CNCR?

IBB tracks NASDAQ Biotechnology Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: iShares and Exchange Traded Concepts. Their fees differ too: 0.47% for IBB and 0.79% for CNCR.